Scarica l'app Stockscreener
25.49
1.07%
0.27
Pre-mercato:
25.99
0.50
+1.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$25.22
Aprire:
$25.5
Volume 24 ore:
57,637
Relative Volume:
0.98
Capitalizzazione di mercato:
$315.65M
Reddito:
$9.71M
Utile/perdita netta:
$-29.96M
Rapporto P/E:
-7.3247
EPS:
-3.48
Flusso di cassa netto:
$-14.79M
1 W Prestazione:
-16.40%
1M Prestazione:
-21.91%
6M Prestazione:
+6.88%
1 anno Prestazione:
-6.11%
Intervallo 1D:
$24.96
$25.93
Intervallo di 1 settimana:
$24.96
$34.79
Portata 52W:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Nome
Xoma Royalty Corp
Settore
Industria
Telefono
510-204-7239
Indirizzo
2200 POWELL STREET, EMERYVILLE, CA
Confronta XOMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
25.49 | 312.30M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | The Benchmark Company | Buy |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2021-09-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-06-29 | Iniziato | Aegis Capital | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-17 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-05 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2017-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2016-11-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-11 | Reiterato | Wedbush | Outperform |
| 2015-07-23 | Downgrade | Jefferies | Buy → Hold |
| 2015-07-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Ripresa | ROTH Capital | Buy |
| 2014-04-29 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-03-11 | Downgrade | MLV & Co | Buy → Hold |
| 2014-03-05 | Reiterato | Ladenburg Thalmann | Buy |
| 2013-10-31 | Reiterato | MLV & Co | Buy |
| 2013-05-09 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-14 | Iniziato | Cowen & Co | Outperform |
| 2011-03-31 | Reiterato | MLV Capital | Buy |
| 2011-03-23 | Reiterato | RBC Capital Mkts | Outperform |
| 2011-01-06 | Reiterato | Ladenburg Thalmann | Buy |
| 2011-01-04 | Reiterato | Wedbush | Outperform |
Mostra tutto
Xoma Royalty Corp Borsa (XOMA) Ultime notizie
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire Inc.
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA (NASDAQ:XOMAO) Trading 0.8% Higher – Time to Buy? - Defense World
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - The Manila Times
Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks
XOMA Royalty (Nasdaq: XOMA) completes $2.035 per share Mural Oncology takeover - Stock Titan
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Why XOMA Royalty Corporation (X0M1) stock could be top winnerJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Will XOMA Royalty Corporation (X0M1) stock test record highs in 20252025 Price Action Summary & Weekly High Return Forecasts - Newser
Why XOMA Royalty Corporation (X0M1) stock appeals to dividend investorsEarnings Recap Report & Capital Efficient Trade Techniques - Newser
What earnings margins imply for XOMA Royalty Corporation(X0M) stockIPO Watch & Risk Managed Investment Strategies - Newser
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com India
Irish court approves XOMA Royalty’s acquisition of Mural Oncology - Investing.com
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) wins Irish court nod for XOMA deal, Nasdaq trading expected to end Dec. 4 - Stock Titan
Is XOMA Royalty Corporation (X0M1) stock a defensive play amid uncertaintyMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
How robust is XOMA Royalty Corporation(X0M) stock financial position - Newser
XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition - Nasdaq
Mural Oncology announces final cash consideration payable on acquisition close - MSN
XOMA Royalty to acquire Mural Oncology for $2.035 per share By Investing.com - Investing.com Nigeria
XOMA Royalty to acquire Mural Oncology for $2.035 per share - Investing.com India
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty - The Globe and Mail
Mural Oncology plc Announces Final Determination of Additional Price Per Share in Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) to Be Acquired by XOMA Royalty for $2.035 Cash - Stock Titan
Xoma Royalty Corp Azioni (XOMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):